Ser104
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.2
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser104  -  BIM (human)

Site Information
FsFDTDRsPAPMSCD   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 449602

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 3 ) , mass spectrometry ( 1 ) , mutation of modification site ( 2 , 3 ) , western blotting ( 3 )
Disease tissue studied:
HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, triple negative ( 1 )
Relevant cell line - cell type - tissue:

References 

1

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

2

Moustafa-Kamal M, et al. (2013) BimEL is phosphorylated at mitosis by Aurora A and targeted for degradation by ╬▓TrCP1. Cell Death Differ 20, 1393-403
23912711   Curated Info

3

Luo S, et al. (2012) Bim inhibits autophagy by recruiting beclin 1 to microtubules. Mol Cell 47, 359-70
22742832   Curated Info

4

Gilley R, et al. (2012) CDK1, not ERK1/2 or ERK5, is required for mitotic phosphorylation of BIM(EL). Cell Signal 24, 170-80
21924351   Curated Info